Association Between ACE2 and Lung Diseases

References

• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) Converts angiotensin I to angiotensin 1-9. Circul Res. 2000;87(5):E1–9. doi:10.1161/01.RES.87.5.e1
   PubMed Web of Science ®Google Scholar
• Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. doi:10.3390/v11010059
   PubMed Web of Science ®Google Scholar
• Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. Circulation. 2020;142(5):426–428. doi:10.1161/CIRCULATIONAHA.120.047049
   PubMed Web of Science ®Google Scholar
• Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217(6). doi:10.1084/jem.20200678
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:10.1002/path.1570
   PubMed Web of Science ®Google Scholar
• Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614–14621. doi:10.1128/JVI.79.23.14614-14621.2005
   PubMed Web of Science ®Google Scholar
• Lumbers ER, Delforce SJ, Pringle KG, Smith GR. The lung, the heart, the novel coronavirus, and the renin-angiotensin system; the need for clinical trials. Front Med. 2020;7:248. doi:10.3389/fmed.2020.00248
   Web of Science ®Google Scholar
• Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circul Res. 2020;126(10):1456–1474. doi:10.1161/CIRCRESAHA.120.317015
   PubMed Web of Science ®Google Scholar
• Jacobs M, Van Eeckhoutte HP, Wijnant SRA, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Europ resp J. 2020;56(2):2002378. doi:10.1183/13993003.02378-2020
   PubMed Web of Science ®Google Scholar
• Liu A, Zhang X, Li R, et al. Overexpression of the SARS-CoV −2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia. J Pathol. 2021;253(1):17–30. doi:10.1002/path.5555
   PubMed Web of Science ®Google Scholar
• Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Europ resp J. 2020;55(5). doi:10.1183/13993003.00688-2020
   Web of Science ®Google Scholar
• Samelson AJ, Tran QD, Robinot R, et al. BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nat Cell Biol. 2022;24(1):24–34. doi:10.1038/s41556-021-00821-8
   PubMed Web of Science ®Google Scholar
• Nikiforuk AM, Kuchinski KS, Twa DDW, et al. The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: a cross-sectional study of people tested for COVID-19 in British Columbia, Canada. EBioMedicine. 2021;66:103316. doi:10.1016/j.ebiom.2021.103316
   PubMed Web of Science ®Google Scholar
• Sepe S, Rossiello F, Cancila V, et al. DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging. EMBO Rep. 2022;23(2):e53658. doi:10.15252/embr.202153658
   PubMed Web of Science ®Google Scholar
• Jin X, Zhang J, Li Y, et al. Exogenous chemical exposure increased transcription levels of the host virus receptor involving coronavirus infection. Environ Sci Technol. 2022;56(3):1854–1863. doi:10.1021/acs.est.1c07172
   PubMed Web of Science ®Google Scholar
• Weekly epidemiological update on COVID-19; 2023. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2023. Accessed April 20, 2024.
   Google Scholar
• Gorbalenya AE, Baker SC, Baric RS. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiol. 2020;5(4):536–544. doi:10.1038/s41564-020-0695-z
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. doi:10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi:10.1126/science.abb2507
   PubMed Web of Science ®Google Scholar
• Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022;29(3). doi:10.1093/jtm/taac037
   Web of Science ®Google Scholar
• Chen F, Zhang Y, Li X, Li W, Liu X, Xue X. The Impact of ACE2 Polymorphisms on COVID-19 disease: susceptibility, severity, and therapy. Front Cell Infect Microbiol. 2021;11:753721. doi:10.3389/fcimb.2021.753721
   PubMed Web of Science ®Google Scholar
• Khani E, Khiali S, Beheshtirouy S, Entezari-Maleki T. Potential pharmacologic treatments for COVID-19 smell and taste loss: a comprehensive review. Eur J Pharmacol. 2021;912:174582. doi:10.1016/j.ejphar.2021.174582
   PubMed Web of Science ®Google Scholar
• Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6(31). doi:10.1126/sciadv.abc5801
   PubMed Web of Science ®Google Scholar
• Yıldırım F, Karaman İ, Kaya A. Current situation in ARDS in the light of recent studies: classification, epidemiology and pharmacotherapeutics. Tuberkuloz ve toraks. 2021;69(4):535–546. doi:10.5578/tt.20219611
   PubMed Web of Science ®Google Scholar
• Banavasi H, Nguyen P, Osman H, Soubani AO. Management of ARDS - what works and what does not. Am J Med Sci. 2021;362(1):13–23. doi:10.1016/j.amjms.2020.12.019
   PubMed Web of Science ®Google Scholar
• Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416–2430. doi:10.1016/S0140-6736(16)00578-X
   PubMed Web of Science ®Google Scholar
• Yilin Z, Yandong N, Faguang J. Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. Burns. 2015;41(7):1468–1477. doi:10.1016/j.burns.2015.04.010
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi:10.1038/nature03712
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92(7):726–730. doi:10.1002/jmv.25785
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020;14(2):126–135. doi:10.1007/s11684-020-0767-8
   PubMed Web of Science ®Google Scholar
• Rurua M, Pachkoria E, Sanikidze T, et al. Impact of the Angiotensin-Converting Enzyme (ACE) inhibitors on the course of the acute respiratory distress syndrome (ARDS) developed during COVID-19 and Other severe respiratory infections under hyperferritinemia conditions: a cohort study. Clin Med Insights. 2023;17:11795484231180391. doi:10.1177/11795484231180391
   Google Scholar
• Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020;96(1137):403–407. doi:10.1136/postgradmedj-2020-137935
   PubMed Web of Science ®Google Scholar
• Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. New Engl J Med. 2015;373(2):111–122. doi:10.1056/NEJMoa1411532
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi:10.1016/j.rmed.2020.105938
   PubMed Web of Science ®Google Scholar
• Athanazio R. Airway disease: similarities and differences between asthma, COPD and bronchiectasis. Clinics. 2012;67(11):1335–1343. doi:10.6061/clinics/2012(11)19
   PubMed Web of Science ®Google Scholar
• Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-6
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Bando M, Miyazawa T, Shinohara H, Owada T, Terakado M, Sugiyama Y. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease. Respirology. 2012;17(3):493–498. doi:10.1111/j.1440-1843.2011.02116.x
   PubMed Web of Science ®Google Scholar
• Teramoto S, Suzuki M, Matsuse T, Ishii T, Fukuchi Y, Ouchi Y. Effects of angiotensin-converting enzyme inhibitors on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary disease. Jpn J Pharmacol. 2000;83(1):56–62. doi:10.1016/S0021-5198(19)30627-4
   PubMedGoogle Scholar
• Bullock GR, Steyaert I, Bilbe G, et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Bio. 2001;115(2):117–124. doi:10.1007/s004180000235
   PubMed Web of Science ®Google Scholar
• Xue T, Wei N, Xin Z, Qingyu X. Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease. Inhalation Toxicol. 2014;26(1):14–22. doi:10.3109/08958378.2013.850563
   PubMed Web of Science ®Google Scholar
• Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Europ resp J. 2020;56(2):2002108. doi:10.1183/13993003.02108-2020
   PubMed Web of Science ®Google Scholar
• Fließer E, Birnhuber A, Marsh LM, et al. Dysbalance of ACE2 levels - a possible cause for severe COVID-19 outcome in COPD. J Pathol Clin Res. 2021;7(5):446–458. doi:10.1002/cjp2.224
   PubMedGoogle Scholar
• Fraser DD, Patel MA, Van Nynatten LR, et al. Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon. 2023;9(1):e12704. doi:10.1016/j.heliyon.2022.e12704
   PubMed Web of Science ®Google Scholar
• Nath KD, Burel JG, Shankar V, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chronic Obstr. 2014;9:51–56. doi:10.2147/COPD.S53590
   PubMed Web of Science ®Google Scholar
• Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259. doi:10.1016/S0140-6736(17)32154-2
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(1):80–88.e88. doi:10.1016/j.jaci.2020.05.004
   PubMed Web of Science ®Google Scholar
• Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021;76(2):483–496. doi:10.1111/all.14517
   PubMed Web of Science ®Google Scholar
• Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. Clin Rev Allergy Immunol. 2020;59(1):78–88. doi:10.1007/s12016-020-08797-3
   PubMed Web of Science ®Google Scholar
• Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020;11(1):5139. doi:10.1038/s41467-020-18781-2
   PubMed Web of Science ®Google Scholar
• Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, et al. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015;172(9):2330–2342. doi:10.1111/bph.13057
   PubMed Web of Science ®Google Scholar
• Loubet P, Samih-Lenzi N, Galtier F, et al. Factors associated with poor outcomes among adults hospitalized for influenza in France: a three-year prospective multicenter study. J Clin Virol. 2016;79:68–73. doi:10.1016/j.jcv.2016.04.005
   PubMed Web of Science ®Google Scholar
• Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741. doi:10.1111/all.14238
   PubMed Web of Science ®Google Scholar
• Sunjaya AP, Allida SM, Di Tanna GL, Jenkins CR. Asthma and COVID-19 risk: a systematic review and meta-analysis. Europ resp J. 2022;59(3):2101209. doi:10.1183/13993003.01209-2021
   PubMed Web of Science ®Google Scholar
• Otunla A, Rees K, Dennison P, et al. Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses. BMJ Evidence Based Med. 2022;27(5):263–273. doi:10.1136/bmjebm-2021-111788
   PubMedGoogle Scholar
• Chhapola Shukla S. ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19. Europ Archiv Oto-Rhino-Laryngol. 2021;278(7):2637–2640. doi:10.1007/s00405-020-06408-7
   PubMed Web of Science ®Google Scholar
• Bloom CI. Covid-19 pandemic and asthma: what did we learn? Respirology. 2023;28(7):603–614. doi:10.1111/resp.14515
   PubMed Web of Science ®Google Scholar
• Gottschalk G, Knox K, Roy A. ACE2: at the crossroad of COVID-19 and lung cancer. Gene Rep. 2021;23:101077. doi:10.1016/j.genrep.2021.101077
   PubMed Web of Science ®Google Scholar
• Zhang L, Han X, Shi Y. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues. Infect Genet Evol. 2020;85:104428. doi:10.1016/j.meegid.2020.104428
   PubMed Web of Science ®Google Scholar
• Qian YR, Guo Y, Wan HY, et al. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep. 2013;29(6):2408–2414. doi:10.3892/or.2013.2370
   PubMed Web of Science ®Google Scholar
• Cheng Q, Zhou L, Zhou J, Wan H, Li Q, Feng Y. ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC. Oncol Rep. 2016;36(3):1403–1410. doi:10.3892/or.2016.4967
   PubMed Web of Science ®Google Scholar
• Xu K, Han H, Luo Y, Ye H, Lin H, Ni L. The angiotensin-converting enzyme inhibitory state promotes the transformation of non-small cell lung cancer blood supply pattern toward vasculogenic mimicry formation. Front Oncol. 2021;11:663671. doi:10.3389/fonc.2021.663671
   PubMed Web of Science ®Google Scholar
• Yao T, Wu Z, Wang Z, et al. Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study. Front Pharmacol. 2023;14:1267924. doi:10.3389/fphar.2023.1267924
   PubMed Web of Science ®Google Scholar
• Wu Z, Yao T, Wang Z, et al. Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128(2):168–176. doi:10.1038/s41416-022-02029-5
   PubMed Web of Science ®Google Scholar
• Shenoy V, Kwon KC, Rathinasabapathy A, et al. Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension. 2014;64(6):1248–1259. doi:10.1161/HYPERTENSIONAHA.114.03871
   PubMed Web of Science ®Google Scholar
• Hampl V, Herget J, Bíbová J, et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiolog Res. 2015;64(1):25–38. doi:10.33549/physiolres.932861
   PubMed Web of Science ®Google Scholar
• Yamazato Y, Ferreira AJ, Hong KH, et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension. 2009;54(2):365–371. doi:10.1161/HYPERTENSIONAHA.108.125468
   PubMed Web of Science ®Google Scholar
• Zhang H, Rostami MR, Leopold PL, et al. Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium. Am J Respir Crit Care Med. 2020;202(2):219–229. doi:10.1164/rccm.202003-0541OC
   PubMed Web of Science ®Google Scholar
• Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. Europ resp J. 2020;55(6):2001261. doi:10.1183/13993003.01261-2020
   PubMed Web of Science ®Google Scholar